Conclusions
myocardial injury, breast cancer
BREAST CANCER
In breast cancer patients treated with doxorubicin, co-treatment with either metformin or donepezil did not prevent myocardial injury. Neither metformin nor donepezil attenuated the reduction in LVEF or GLS after doxorubicin treatment. However, at mitochondria level, doxorubicin caused an impaired mitochondrial function. Metformin was the only interventional drug that could preserve mitochondrial respiration during doxorubicin therapy. Future studies should explore possible cardioprotective effects of metformin.